China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement with Intas Pharmaceuticals Ltd., granting the Indian firm exclusive commercialization rights to its BAT2506, a biosimilar version of Johnson & Johnson’s Simponi (golimumab), in the United States.
Details of the Agreement
Under the terms of the agreement, Bio-Thera will be responsible for the research and development, manufacturing, and commercial supply of BAT2506. Intas Pharmaceuticals will pay Bio-Thera up to USD 164.5 million in total, including an upfront payment of USD 21 million and milestone payments of up to USD 143.5 million, along with double-digit royalties based on net sales.
Product Background
Golimumab is a human tumor necrosis factor-α (TNF-α) monoclonal antibody (mAb). BAT2506, the biosimilar version, has completed global Phase III clinical trials and is now awaiting regulatory decisions in the European Union (EU).-Fineline Info & Tech
